The wait to see cardiovascular outcomes data on Amgen Inc.’s Repatha (evolocumab) and Sanofi/Regeneron Pharmaceuticals Inc.’s Praluent (alirocumab) just got even more interesting after Pfizer Inc. announced Nov. 1 that it is discontinuing development of its late-stage PCSK9 inhibitor bococizumab due to the clinical profile.
The news – coinciding with the company’s third quarter sales and earnings report – surprised investors because PCSK9 is a fairly well understood mechanism of action with two approved drugs already on the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?